Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.
David O’Malley, MD, of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), presented the preliminary study results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on Sept. 18. O’Malley was the lead presenter for both trials, which were sponsored by Agenus Inc.
Each study involved more than 150 patients with recurrent or metastatic cervical cancer from cancer treatment centers across the United States and Europe. All patients were previously treated with platinum-based chemotherapy as a first-line therapy. The two independent but consecutive phase II trials tested a new immune-based agent
Bioengineers are devising a hot new technology to remotely control the positioning and timing of cell functions to build 3-dimensional, artificial, living tissues.
The labs of Kelly Stevens at the UW Medicine Institute of Stem Cell and Regenerative Medicine in Seattle, and Jordan Miller at Rice University in Houston, are collaborating to develop bio-printed, organ-like tissues, such as liver and lung constructs.
The Steven’s lab has the long-term vision of building liver tissues that simulate some of the many, complex functions of the organ. Those artificial tissues could be used to study, for example, how drugs or toxins act on the liver.
This vital organ is prone to damage from infections, medications, poisons, and common intoxicants, like alcohol. Liver disease affects more than 500 million people worldwide and accounts for more than 2 million deaths each year.
Eventually, researchers would like to be able engineer artificial tissues that could be
SHANGHAI (Reuters) – Chinese chipmaker Semiconductor Manufacturing International Corporation has undertaken “preliminary exchanges” with the U.S. Bureau of Industry and Security regarding export restrictions, the company said on Sunday in a filing.
“The Company is conducting assessments on the relevant impact of such export restrictions on the company’s production and operation activities,” the filing to the Hong Kong Stock Exchange said.
SMIC also said it has been operating in compliance with the relevant laws and regulations of all jurisdictions where it performs its businesses.
The company also advised shareholders and potential investors “to exercise caution when dealing in the securities of the Company.”
In September, Reuters reported that the Bureau of Industry and Security under the Department of Commerce had issued letters informing
LAS VEGAS, NV / ACCESSWIRE / September 24, 2020 / Golden Triangle Ventures, Inc. (OTC PINK:TOMI) has made significant advances on its technology division under HyFrontier Technologies, Inc. The company is currently testing its HyGrO technology on many applications and plants. The company is pleased to announce the preliminary results on our CBD Hemp test with Colorado Hemp Services which is being grown with the HyGrO technology against a Control Test, now underway in Pueblo Colorado.
Travis Nelson, Principal of Colorado Hemp Services, states, “We are overly satisfied with the results we are seeing from watering our plants with HyFrontier Technologies’ HyGrO unit. We are approaching harvest soon and we are seeing a much larger flower set. We look forward to testing all the flowers at a certified testing facility to compare cannabinoid profiles after harvest. So far, the leaves on the HyGrO side of the test are greener and